Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients
Nonalcoholic fatty liver disease (NAFLD) refers to excess fat accumulation in the liver. In animal experiments and human kinetic study, we found that administration of combined metabolic activators (CMAs) promotes the oxidation of fat, attenuates the resulting oxidative stress, activates mitochondri...
Main Authors: | , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
John Wiley and Sons Inc
2021
|
Subjects: | |
Online Access: | View Fulltext in Publisher |